The story of entrepreneurship is played out every day in Yangpu... Listen to the stories of this group of young people who are involved in the field of biomedical construction!
//
In 2021, Shanghai Xuanyan Biotechnology Co., Ltd. was established. Today, Xuanyan Biotech has carried out in-depth cooperation with more than 20 third-class hospitals, independently developed more than 100 projects, applied for more than 10 Sino-US patents, published more than 20 academic papers, and the total impact factor exceeded 200.
Xiao Siyu, co-founder of Shanghai Xuanyan Biotechnology Co., Ltd., graduated from Fudan University with a bachelor's degree, and then chose to study abroad and obtained a doctorate in biology from the University of Houston. This year, Xiao Siyu won a new "title", and she and her team won the champion of the 9th China International "Internet +" College Students Innovation and Entrepreneurship Competition Shanghai Division with the project of "AI Big Data-driven Target Mining Innovative Drug Development Platform and Auxiliary Diagnosis Development". The team uses the combination of AI and innovative drug development to solve more clinical dilemmas, use the most cutting-edge technology to protect the few groups around them, and make the most traditional industries shine with new vitality.
Xiao Siyu, co-founder of Shanghai Xuanyan Biotechnology Co., Ltd
Xiao Siyu has a group of like-minded friends, all of whom are doctors in the field of biomedicine, including Cao Xuanye, a small partner who has experience in overseas medical giants. He also graduated from Fudan University and received his Ph.D. in genetics from Baylor College of Medicine. In work and life, they are both friends and strong supporters of each other, working together to overcome biomedical problems.
Co-founder of Xuanyan Bio Cao Xuanye
The vigorous development of the biomedical industry is the result of the integration and development of cutting-edge science and technology such as biotechnology and information technology. Through the combination of AI technology and real clinical samples, Xuanyan Biotech has developed an AI-assisted diagnosis and treatment system, and has also discovered new drug targets, which can not only directly diagnose the disease, but also pay more attention to the combination with the development of the disease, predict the course of the disease, and then treat the disease. At the same time, it integrates new technologies and new models such as AI system omics, AI molecular mechanism exploration, and AI medical imaging, accurately targets clinical problems, and assists in the diagnosis of disease processes and prognosis.
Talking about self-employment, Xiao Siyu said that the original idea was to treat diseases and save people. From finding targets, sample collection, integrative omics, medical imaging AI big data analysis, and finally project research, it is challenging for any team to break through the barriers of resources and technology at the same time. "Where there is a clinical need, there will be us. In the future, we will continue to develop more 'AI+' technologies to help more people. Xiao Siyu said.
Xiao Siyu said that Xuanyan Biotech will continue to study the upstream target business, rely on AI technology to continue to expand auxiliary diagnosis development projects, deepen cooperation with hospitals, solidly promote the research and development of new drugs, and use high-precision technology to create the simplest, effective and beneficial "medical weapon". There is a little light, a little light, keep the "golden 24 hours" of treatment, so that every critically ill patient is not missed.
Text/Image: Wu Jie
Editor: Wu Baixin